JP2025513502A5 - - Google Patents
Info
- Publication number
- JP2025513502A5 JP2025513502A5 JP2024562212A JP2024562212A JP2025513502A5 JP 2025513502 A5 JP2025513502 A5 JP 2025513502A5 JP 2024562212 A JP2024562212 A JP 2024562212A JP 2024562212 A JP2024562212 A JP 2024562212A JP 2025513502 A5 JP2025513502 A5 JP 2025513502A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- aqueous composition
- pharmaceutically acceptable
- acceptable salt
- rilpivirine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333556P | 2022-04-22 | 2022-04-22 | |
| US63/333,556 | 2022-04-22 | ||
| EP22173922 | 2022-05-17 | ||
| EP22173922.0 | 2022-05-17 | ||
| PCT/EP2023/060689 WO2023203258A1 (en) | 2022-04-22 | 2023-04-24 | Liquid compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513502A JP2025513502A (ja) | 2025-04-24 |
| JP2025513502A5 true JP2025513502A5 (cg-RX-API-DMAC7.html) | 2026-05-08 |
Family
ID=86316741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024562212A Pending JP2025513502A (ja) | 2022-04-22 | 2023-04-24 | 液体組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250268896A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511003A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513502A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403543A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249515A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202408516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023203258A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| WO2009128917A2 (en) * | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| AU2020344675B2 (en) * | 2019-09-13 | 2026-06-25 | Halozyme Hypercon, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| WO2022109555A1 (en) | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
-
2023
- 2023-04-24 CN CN202380048796.5A patent/CN119403543A/zh active Pending
- 2023-04-24 TW TW112115225A patent/TW202408516A/zh unknown
- 2023-04-24 US US18/858,242 patent/US20250268896A1/en active Pending
- 2023-04-24 CA CA3249515A patent/CA3249515A1/en active Pending
- 2023-04-24 WO PCT/EP2023/060689 patent/WO2023203258A1/en not_active Ceased
- 2023-04-24 EP EP23722289.8A patent/EP4511003A1/en active Pending
- 2023-04-24 JP JP2024562212A patent/JP2025513502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017036306A (ja) | 経口投与型コルチコステロイド組成物 | |
| JP2024156754A5 (cg-RX-API-DMAC7.html) | ||
| US20220304934A1 (en) | Brivaracetam pharmaceutical composition, preparation method therefor and use thereof | |
| US20080152712A1 (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
| CN105338969A (zh) | 具有改善的稳定性的包含左西替利嗪和孟鲁司特的复合颗粒制剂 | |
| US20240082195A1 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| JP6488003B2 (ja) | 安定なモンテルカスト溶液 | |
| US20170258749A1 (en) | Oseltamivir Compositions | |
| KR20210158795A (ko) | 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물 | |
| JP2005523329A5 (cg-RX-API-DMAC7.html) | ||
| KR102762379B1 (ko) | 안과용 조성물 | |
| WO2004069280A1 (en) | Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent | |
| JP2006008684A (ja) | ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物 | |
| EP3013316B1 (en) | Stable intravenous formulation | |
| JPH10502616A (ja) | Dx−52−1化合物の安定化法及びその凍結乾燥組成物 | |
| JPH0249720A (ja) | 難溶性薬剤組成物 | |
| CN116098864A (zh) | 一种利那洛肽干混悬剂及其制备方法 | |
| JP2025513501A5 (cg-RX-API-DMAC7.html) | ||
| TWI918738B (zh) | 布瓦西坦藥物組合物、其製備方法及應用 | |
| JP2001187735A (ja) | 安定なニコランジル含有粉末の製造法 | |
| AU2021286284B2 (en) | Antimicrobial compositions with effervescent agents | |
| WO2014071743A1 (zh) | 含有抗真菌药物和乳酸盐缓冲剂的组合物 | |
| ES2629103T3 (es) | Formulación en polvo de valganciclovir | |
| CZ286610B6 (cs) | Intranasální kompozice proti migréně | |
| JPH1180021A (ja) | バンコマイシン注射剤 |